Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
ANTH's Cash-to-Debt is ranked higher than
83% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ANTH: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ANTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: N/A Max: No Debt
Current: No Debt
Interest Coverage No Debt
ANTH's Interest Coverage is ranked higher than
79% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANTH: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ANTH' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: -31.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -38664.83
ANTH's Operating Margin % is ranked lower than
97% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ANTH: -38664.83 )
Ranked among companies with meaningful Operating Margin % only.
ANTH' s Operating Margin % Range Over the Past 10 Years
Min: -39432.41  Med: -20269.47 Max: -1106.53
Current: -38664.83
-39432.41
-1106.53
Net Margin % -37933.79
ANTH's Net Margin % is ranked lower than
97% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. ANTH: -37933.79 )
Ranked among companies with meaningful Net Margin % only.
ANTH' s Net Margin % Range Over the Past 10 Years
Min: -38291.72  Med: -19698.77 Max: -1105.81
Current: -37933.79
-38291.72
-1105.81
ROE % -441.74
ANTH's ROE % is ranked lower than
96% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ANTH: -441.74 )
Ranked among companies with meaningful ROE % only.
ANTH' s ROE % Range Over the Past 10 Years
Min: -582.71  Med: -259.55 Max: -179.7
Current: -441.74
-582.71
-179.7
ROA % -181.99
ANTH's ROA % is ranked lower than
93% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. ANTH: -181.99 )
Ranked among companies with meaningful ROA % only.
ANTH' s ROA % Range Over the Past 10 Years
Min: -414.89  Med: -145.89 Max: -94.5
Current: -181.99
-414.89
-94.5
ROC (Joel Greenblatt) % -7947.71
ANTH's ROC (Joel Greenblatt) % is ranked lower than
85% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. ANTH: -7947.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ANTH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -263793.33  Med: -12857.08 Max: -2880.94
Current: -7947.71
-263793.33
-2880.94
3-Year EBITDA Growth Rate -4.30
ANTH's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. ANTH: -4.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ANTH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -54.6 Max: -4.3
Current: -4.3
3-Year EPS without NRI Growth Rate -1.60
ANTH's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. ANTH: -1.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ANTH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -54 Max: -1.6
Current: -1.6
GuruFocus has detected 2 Warning Signs with Anthera Pharmaceuticals Inc $ANTH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ANTH's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TENX, OTCPK:CDXI, AMEX:CVM, NAS:ARGS, OTCPK:BLUSF, NAS:CYCC, OTCPK:IMUN, OTCPK:BRTX, OTCPK:CRYO, NAS:VTGN, NAS:XTLB, OTCPK:MMIRF, OTCPK:USRM, NAS:CYAN, OTCPK:ATTBF, NAS:ACST, OTCPK:PRTX, OTCPK:WLDFF, NAS:RXII, NAS:KTOV » details
Traded in other countries:6TA2.Germany,
Headquarter Location:USA
Anthera Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapeutics to treat serious diseases.

Anthera Pharmaceuticals INc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.

Top Ranked Articles about Anthera Pharmaceuticals Inc

Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results
Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock
Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura

Sollpura demonstrated comparable maintenance in key measurements of height, weight, and BMI
Sollpura was well tolerated throughout the 20-Week Extension Period HAYWARD, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) today announced the findings from the Extension Period of the Phase 3 SOLUTION, non-inferiority clinical study in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI).  The Extension Period was designed as an observational analysis of the long-term effects of Sollpura and Pancreaze as it pertains to weight, height, BMI, and safety. “We are pleased to see the continued tolerability and maintenance of weight and height in all of the Sollpura treated cystic fibrosis patients with EPI during the Extension Period and in particular, increases in weight and height in patients less than 17 years of age,” stated William Shanahan, Anthera’s Chief Medical Officer. “The 20-Week data provides support that Sollpura may offer patients an alternative to existing, porcine-based pancreatic enzyme replacement therapies.” During the Extension Period (Week 7 through Week 20), all patients treated with Sollpura maintained their weight at 56.4 kg-56.9 kg and all patients treated with Pancreaze maintained their weight at 54.6 kg-54.8 kg.  Both groups showed small increases in height, with Sollpura increasing from 163.2 cm to 163.7 cm, and Pancreaze increasing from 160.6 cm to 160.8 cm.  A modest decrease in body mass index (BMI) was observed in both treatment groups with Sollpura treated patients decreasing from 20.99 kg/m2 to 20.76 kg/m2 and Pancreaze treated patients decreasing from 20.75 kg/m2 to 20.66 kg/m2.  In pediatric patients less than 17 years of age, the key age group for growth and development, similar trends in weight and height were observed in both treatment groups, as shown in the table below.  Patients <17 years of age Sollpura
mean (standard deviation)Pancreaze
mean (standard deviation)Week 7Week 20Week 7Week 20n=15n=15n=20n=19Weight (kg)49.2 (13.8)49.7 (13.1)41.8 (15.1)41.5 (15.0)Height (cm)158.3 (13.8)159.8 (13.3)144.6 (16.6)145.0 (16.8)BMI (kg/m2)19.2 (2.8)19.1 (2.5)19.2 (3.6)19.0 (3.6) Sollpura and Pancreaze were generally well tolerated with 40% and 54% of patients experiencing a treatment emergent adverse event, respectively.  Most of the difference was comprised of a lower rate of infective pulmonary exacerbations of CF in the Sollpura versus Pancreaze arm (9.2% vs. 20.6%) and respiratory disorders (9.3% vs. 15.9%). Proportions of patients experiencing mild, moderate, or serious events in the Sollpura versus Pancreaze arm were 27.7% vs 41.3%, 9.2% vs 11.1% and 3.1% vs 1.6%, respectively.  The rate of serious adverse events was balanced at 4.6% for Sollpura and 6.3% for Pancreaze with no discontinuations in either arm. The Extension Period data concludes the Phase 3 SOLUTION trial.  Anthera plans to initiate a Phase 3 trial, RESULT, (Reliable Emergent Solution Using Liprotamase Treatment) in 1H 2017, with topline data anticipated at the end of 2017 or early 2018.  About SOLUTION The Phase 3 SOLUTION study was designed to evaluate the non-inferiority of Sollpura compared to approved, porcine-derived, enteric-coated pancreatic enzyme replacement therapy when administered at approximately equivalent doses to patients with exocrine pancreatic insufficiency due to cystic fibrosis. The study enrolled patients with exocrine pancreatic insufficiency due to cystic fibrosis who were well controlled on stable PERT therapy, as demonstrated by a coefficient of fat absorption (CFA) of at least 80% at screening. The primary efficacy variable evaluated the change from baseline in CFA following 7 weeks of therapy with either Sollpura or Pancreaze, an alternative porcine PERT to that being taken during screening.  Individualized doses of Sollpura and the PERT comparator were chosen to match the lipase units of pre-study PERT.  Adjustment of the study drug doses was allowed during the first 2 weeks of study based on clinical signs of malabsorption up to a maximum of 150% of baseline but not to exceed 10,000 units/kg/day of lipase. After the Week 7 CFA measurement, patients enrolled into the SOLUTION study were followed through Week 20 for additional assessments of safety and efficacy. About RESULT The Phase 3 RESULT study is designed to evaluate the non-inferiority of Sollpura at individualized doses compared to approved, porcine-derived, enteric-coated pancreatic enzyme replacement therapy when administered to patients with exocrine pancreatic insufficiency due to cystic fibrosis.  The study will enroll patients (N≈150) with exocrine pancreatic insufficiency due to cystic fibrosis who are well controlled on stable PERT therapy at screening, as demonstrated by a coefficient of fat absorption (CFA) of at least 80%.  The primary efficacy variable will evaluate the change from baseline in CFA following treatment through 4 weeks of therapy with either Sollpura or Pancreaze.  Patients randomized to Sollpura will begin at 125% of the baseline porcine lipase dose and may undergo individualized dose adjustments based upon gastrointestinal signs and symptoms up to the lesser of two times the baseline lipase dose or 15,000 lipase units/kg/day in adults or 10,000 lipase units/kg/day in patients ages 7 to less than 17.  Anthera believes that this optimized dosing paradigm will correct for differences in solubility between the lipases in Sollpura and porcine PERTs in the more acidic duodenal pH of patients with cystic fibrosis.  Patients randomized to Pancreaze will begin their dose at the equivalent of their pre-study lipase units/kg/day. Patients randomized to Sollpura will then be followed for an additional 20-Week extension period (total of 24 weeks on study) for additional assessments of weight, height, BMI, and safety. About Sollpura® (liprotamase) Sollpura is a novel, non-porcine PERT containing a proprietary, biotechnology-derived formulation of cross-linked crystalline lipase, crystalline protease, and amorphous amylase with broad substrate specificity, that has been designed for purity (no potential for viral contamination), precise dose standardization, resistance against proteolysis without enteric coating, and stability in acid pH for potency of activity in the proximal small intestine. Sollpura represents potentially the first soluble, stable and non-pig derived enzyme product to offer a solution to people with EPI, including young children and adults, who are either unable to swallow multiple pills or require gastric tubes in order to maintain appropriate nutritional health. About Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency due to cystic fibrosis, and IgA nephropathy. Additional information on Anthera can be found at www.anthera.com. Safe Harbor Statement Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
Investor Relations, Anthera Pharmaceuticals
[email protected]

Read more...
Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

HAYWARD, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) (the “Company”) today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price of $0.50 per share and two tranches of warrants to purchase an aggregate of 60,000,000 shares of its common stock. The gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, are expected to be $15.0 million.  If exercised in full for cash, the warrants could result in additional gross proceeds of up to $31.5 million to the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrants offered in the public offering. The offering is expected to close on or about March 17, 2017, subject to customary closing conditions.
The initial per share exercise price of the Tranche 1 warrants is $0.55 and the initial per share exercise price of the Tranche 2 warrants is $0.50, each subject to adjustment as specified in the warrants.  The Tranche 1 and Tranche 2 warrants will become exercisable on any day on or after the date that the Company publicly announces through the filing of a Current Report on Form 8-K that it will have sufficient authorized shares of common stock (the “Exercisable Date”) and will expire five years following the Exercisable Date and six months following the Exercisable Date, respectively. Rodman & Renshaw, a unit of H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The Company intends to use the net proceeds from the public offering for clinical research and development purposes for SOLLPURA, including the RESULT, SIMPLICITY and EASY trials as well as enabling manufacturing and general corporate purposes. The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-210166) previously filed with, and declared effective by the Securities and Exchange Commission (the "SEC") on April 18, 2016.  A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, New York, 10022, by calling 646-975-6996 or by [email protected] This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Safe Harbor Statement Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about Anthera’s expectations with respect to its public offering, including statements about its intended use of proceeds from the offering. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
Contact Information:

Investor Relations of Anthera Pharmaceuticals, Inc.,
[email protected]

Read more...
ANTH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017

NEW YORK, March 14, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) securities between February 10, 2015 and December 27, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/anthera-pharmaceuticals-inc. There is no cost or obligation to you. According to the complaint, throughout the Class Period Anthera made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that: (i) patients were not improving in the CHABLIS-SC1 clinical trial; and (ii) there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses. On November 10, 2016, the Company issued a press release announcing that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of SLE failed to meet its primary endpoint. Following this news, shares of Anthera fell approximately 32% to close at $1.90 on November 10, 2016. Then on December 27, 2016, the Company issued another press release, announcing that the Solution clinical study in cystic fibrosis patients with EPI missed the CFA non-inferiority margin of the primary modified Intent to Treat. Following this news, shares of Anthera fell approximately 63% to close at $0.74 on December 28, 2016. If you suffered a loss in Anthera you have until April 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/anthera-pharmaceuticals-inc. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:   
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Anthera Pharmaceuticals, Inc. (ANTH) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

STEVENSON, Md., March 14, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Anthera Pharmaceuticals, Inc. ( ANTH) (“Anthera” or the “Company”) common stock during the period between February 10, 2015 and December 27, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until April 17, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Anthera common stock during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that patients were not improving in the CHABLIS-SC1 clinical trial and there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses. According to the complaint, following a November 10, 2016 press release announcing that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systematic lupus erythematosus failed to meet its primary endpoint, and a December 27, 2016 press release announcing that the Solution Study in cystic fibrosis patients with exocrine pancreatic insufficiency missed the Coefficient of Fat Absorption non-inferiority margin of the primary modified Intent to Treat, the value of Anthera shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in Anthera common stock purchased on or after February 10, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

HAYWARD, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) (the “Company”) today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.  In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrants offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Rodman & Renshaw, a unit of H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The Company intends to use the net proceeds from the public offering for clinical research and development purposes for SOLLPURA, including the RESULT, SIMPLICITY and EASY trials as well as enabling manufacturing and general corporate purposes. The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-210166) previously filed with, and declared effective by the Securities and Exchange Commission (the "SEC") on April 18, 2016.  A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, New York, 10022, by calling 646-975-6996 or by e-mailing [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Safe Harbor Statement Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about Anthera’s expectations with respect to its public offering, including statements about its intended use of proceeds from the offering. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
Contact Information:

Investor Relations of Anthera Pharmaceuticals, Inc.,
[email protected]


Read more...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc.

Sets Lead Plaintiff Deadline of April 17, 2017 -- ANTH

NEW YORK, March 03, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Anthera Pharmaceuticals, Inc. (“Anthera”) (NASDAQ:ANTH) between February 10, 2015 and December 27, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Clevlen v. Anthera Pharmaceuticals, Inc., et al. (Case No. 3:17-cv-715) in the USDC for the Northern District of California. Click here to view the complaint. To get more information go to: http://www.zlk.com/pslra/anthera-pharmaceuticals-inc or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that, among other allegations, throughout the Class Period, Anthera made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that: (i) patients were not improving in the CHABLIS-SC1 clinical trial; and (ii) there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses. On November 10, 2016, the Company issued a press release announcing that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of SLE failed to meet its primary endpoint. Following this news, shares of Anthera fell approximately 32% to close at $1.90 on November 10, 2016. Then on December 27, 2016, the Company issued another press release, announcing that the Solution clinical study in cystic fibrosis patients with EPI missed the CFA non-inferiority margin of the primary modified Intent to Treat. Following this news, shares of Anthera fell approximately 63% to close at $0.74 on December 28, 2016. Take Action: if you suffered a loss in Anthera you have until April 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...

Ratios

vs
industry
vs
history
PB Ratio 6.93
NAS:ANTH's PB Ratio is ranked lower than
73% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NAS:ANTH: 6.93 )
Ranked among companies with meaningful PB Ratio only.
NAS:ANTH' s PB Ratio Range Over the Past 10 Years
Min: 2.4  Med: 5.7 Max: 23.49
Current: 6.93
2.4
23.49
EV-to-EBIT 0.07
NAS:ANTH's EV-to-EBIT is ranked higher than
99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. NAS:ANTH: 0.07 )
Ranked among companies with meaningful EV-to-EBIT only.
NAS:ANTH' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.6  Med: -2.55 Max: 0.1
Current: 0.07
-11.6
0.1
EV-to-EBITDA 0.07
NAS:ANTH's EV-to-EBITDA is ranked higher than
99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. NAS:ANTH: 0.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
NAS:ANTH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.8  Med: -2.6 Max: 0.1
Current: 0.07
-11.8
0.1
Current Ratio 3.73
NAS:ANTH's Current Ratio is ranked lower than
53% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NAS:ANTH: 3.73 )
Ranked among companies with meaningful Current Ratio only.
NAS:ANTH' s Current Ratio Range Over the Past 10 Years
Min: 0.15  Med: 3.48 Max: 16.1
Current: 3.73
0.15
16.1
Quick Ratio 3.73
NAS:ANTH's Quick Ratio is ranked lower than
51% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ANTH: 3.73 )
Ranked among companies with meaningful Quick Ratio only.
NAS:ANTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.15  Med: 3.48 Max: 16.1
Current: 3.73
0.15
16.1
Days Sales Outstanding 251.72
NAS:ANTH's Days Sales Outstanding is ranked lower than
92% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NAS:ANTH: 251.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAS:ANTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.36  Med: 37.36 Max: 251.72
Current: 251.72
37.36
251.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -33.30
NAS:ANTH's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NAS:ANTH: -33.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAS:ANTH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -272.5  Med: -59.2 Max: 0
Current: -33.3
-272.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 9.71
NAS:ANTH's Price-to-Net-Current-Asset-Value is ranked lower than
62% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NAS:ANTH: 9.71 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NAS:ANTH' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.95  Med: 5.61 Max: 29.78
Current: 9.71
1.95
29.78
Price-to-Tangible-Book 6.93
NAS:ANTH's Price-to-Tangible-Book is ranked lower than
63% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. NAS:ANTH: 6.93 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NAS:ANTH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.95  Med: 4.7 Max: 17.5
Current: 6.93
1.95
17.5
Earnings Yield (Greenblatt) % 1428.57
NAS:ANTH's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NAS:ANTH: 1428.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAS:ANTH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3112.1  Med: -36.8 Max: 7813.1
Current: 1428.57
-3112.1
7813.1

More Statistics

Revenue (TTM) (Mil) $0.15
EPS (TTM) $ -12.59
Beta2.83
Short Percentage of Float28.94%
52-Week Range $1.54 - 32.00
Shares Outstanding (Mil)10.08

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.38 -1.57 -0.81
EPS without NRI ($) -1.38 -1.57 -0.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}